3 - BioNexus Gene Lab Corp (0001737523) (Issuer)

3 - BioNexus Gene Lab Corp (0001737523) (Issuer)

3 - BioNexus Gene Lab Corp (0001737523) (Issuer)

3 - BioNexus Gene Lab Corp (0001737523) (Issuer)

3 - BioNexus Gene Lab Corp (0001737523) (Issuer)

3 - BioNexus Gene Lab Corp (0001737523) (Issuer)

3 - BioNexus Gene Lab Corp (0001737523) (Issuer)

3 - BioNexus Gene Lab Corp (0001737523) (Issuer)

3 - BioNexus Gene Lab Corp (0001737523) (Issuer)

3 - BioNexus Gene Lab Corp (0001737523) (Issuer)

DEF 14A - BioNexus Gene Lab Corp (0001737523) (Filer)

8-K - BioNexus Gene Lab Corp (0001737523) (Filer)

10-Q - BioNexus Gene Lab Corp (0001737523) (Filer)

PRE 14A - BioNexus Gene Lab Corp (0001737523) (Filer)

8-K - BioNexus Gene Lab Corp (0001737523) (Filer)

8-K - BioNexus Gene Lab Corp (0001737523) (Filer)

S-3 - BioNexus Gene Lab Corp (0001737523) (Filer)

8-K - BioNexus Gene Lab Corp (0001737523) (Filer)

10-Q - BioNexus Gene Lab Corp (0001737523) (Filer)

NT 10-Q - BioNexus Gene Lab Corp (0001737523) (Filer)

KUALA LUMPUR, Malaysia, Dec. 03, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ:BGLC) ("BGLC" or the "Company"), a biotechnology company advancing precision diagnostics and gene-based technologies, today announced the formal completion of its strategic transaction with Fidelion Diagnostics Pte. Ltd. ("Fidelion") and Tongshu Biotechnology. With the closing of the agreements, BGLC has become a strategic shareholder in Fidelion Diagnostics and secured exclusive commercial rights for the VitaGuard™ Tumor-Naïve Minimal Residual Disease (MRD) liquid biopsy platform across Southeast Asia (ASEAN) — positioning the Company for long-term growth as precision oncology adoption accelerates a

SHERIDAN, Wyo., Dec. 02, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. ("BGLC" or the "Company"), an emerging provider of precision oncology diagnostics with expanding operations across Southeast Asia, today announced it has entered into a $500,000,000 Equity Purchase Agreement (the "Facility") with ARC Group International Ltd. ("ARC"), a global investment bank and the parent of ARC Group Securities, a FINRA registered broker dealer. The Company believes this facility will provide it with long-term, discretionary access to capital to advance its strategic initiatives, including the commercialization of the VitaGuard™ minimal residual disease (MRD) platform, the addition of contract deve

KUALA LUMPUR, Malaysia and SINGAPORE, Dec. 01, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. ("BGLC") today announced that it has executed an Exclusive Intellectual Property License Agreement for Southeast Asia with Fidelion Diagnostics Pte. Ltd. ("Fidelion") for the VitaGuard™ minimal residual disease ("MRD") liquid biopsy platform. The license is a key condition precedent to the closing of the previously announced Share Subscription and Shareholders' Agreement among BGLC, Fidelion and Tongshu Gene, under which BGLC will become a strategic shareholder in Fidelion and, in return, Fidelion will hold a minority stake in BGLC. Exclusive, Perpetual Rights in Southeast Asia Under the lice

KUALA LUMPUR, Malaysia and SINGAPORE, Nov. 12, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. ("BGLC, ("BGLC," NASDAQ:BGLC) today announced it has entered into definitive agreements with Fidelion Diagnostics Pte. Ltd. ("Fidelion") and Tongshu Biotechnology (Hong Kong) Co., Limited ("Tongshu"), among other parties, to commercialize VitaGuard™, a high-fidelity, tumor-naïve liquid-biopsy platform for minimal residual disease (MRD). The parties executed a Share Subscription and Shareholders' Agreement aligning ownership and governance around a rapid Southeast Asia rollout. The collaboration is intended to support the development and planned commercialization of MRD testing in Southeast Asi

KUALA LUMPUR, Malaysia, Nov. 10, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ:BGLC) ("BioNexus" or the "Company"), a biotechnology company advancing precision diagnostics and gene-based technologies across Asia and the U.S., today announced that it has filed a registration statement on Form S-3 with the U.S. Securities and Exchange Commission ("SEC") to register up to $100 million of securities that may be offered from time to time.Under this shelf, the Company has entered into an Equity Distribution Agreement with Maxim Group LLC, pursuant to which it may, subject to the effectiveness of the registration statement, offer and sell up to $20 million of its common stock through a

KUALA LUMPUR, Malaysia, Oct. 20, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp (NASDAQ:BGLC, "BGLC", or the "Company")), today announced that it has entered into a non-binding Strategic Partnership Term Sheet with BirchBioMed Inc. ("Birch"), a Canadian biopharmaceutical company developing regenerative treatments for organ fibrosis, topical scarring and autoimmune diseases. Under the non-binding term sheet, BGLC would lead Birch's USD $10 million upcoming financing round through a strategic equity investment and collaboration to accelerate commercialization of Birch's FS2 (kynurenic acid) topical platform in Southeast Asia. The partnership is designed to combine BGLC's regional market ac

KUALA LUMPUR, Malaysia, July 30, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. ("BGLC", Nasdaq: BGLC) and Fidelion Diagnostics Pte Ltd, a Singaporean company ("Fidelion") today announced the signing of a term sheet for a strategic, cross-equity partnership that the parties are calling a "DeepSeek-class leap" for liquid biopsy cancer monitoring and AI-driven biotechnology. This builds on BGLC's mission to be a global leader in liquid biopsies, and tumor naïve oncology solutions. Under the term sheet, BGLC will acquire a strategic equity stake in Fidelion and secure exclusive commercial rights to Fidelion's VitaGuard™ minimal-residual-disease (MRD) platform across Southeast Asia (ASEAN

KUALA LUMPUR, Malaysia, April 30, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ:BGLC), a biotechnology company specializing in precision diagnostics and specialty chemical solutions, today announced that it has received official notification from The Nasdaq Stock Market LLC ("Nasdaq") confirming the Company has regained full compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. This important milestone reaffirms the Company's standing as a compliant and growth-focused public company. It marks the successful conclusion of a focused compliance initiative and paves the way for the Company to pursue its bold innovation roadmap, capit

KUALA LUMPUR, Malaysia, April 15, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ:BGLC) ("BioNexus" or the "Company"), a diversified biotechnology and specialty materials group headquartered in Malaysia and incorporated in Wyoming, today announced the filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, with the U.S. Securities and Exchange Commission. The Company's 2024 report showcases a year of strategic realignment, technological advancement, and enhanced corporate governance - positioning BGLC for sustainable long-term growth. Financial Resilience and Market Stability BGLC ended 2024 with a strong cash position of over $4million and total l

KUALA LUMPUR, Malaysia, March 08, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ:BGLC), a technology company dedicated to innovation in the digital and healthcare space, has announced a strategic partnership with ML Tech to optimize the BGLC's Ethereum-based growth strategies. ML Tech is an AI-driven wealth management platform for digital assets regulated by the National Futures Association (NFA), and is headquartered in Miami, Florida. This collaboration follows the announced Ethereum treasury strategy by BGLC, marking its commitment to technological and financial innovation. Through this partnership, BGLC plans to leverage ML Tech's cutting-edge digital asset trading infrastru

KUALA LUMPUR, Malaysia, April 30, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ:BGLC), a biotechnology company specializing in precision diagnostics and specialty chemical solutions, today announced that it has received official notification from The Nasdaq Stock Market LLC ("Nasdaq") confirming the Company has regained full compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. This important milestone reaffirms the Company's standing as a compliant and growth-focused public company. It marks the successful conclusion of a focused compliance initiative and paves the way for the Company to pursue its bold innovation roadmap, capit

SC 13G - BioNexus Gene Lab Corp (0001737523) (Subject)